Cision PR Newswire

NEW YORK, April 15, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Actinium Pharmaceuticals, Inc. (NYSE: ATNM) breached their fiduciary duties to shareholders. 

According to a federal securities lawsuit, Insiders at Actinium Pharmaceuticals caused the company to misrepresent or fail to disclose that (1) the Company's data from the Sierra Trial was unlikely to satisfy the FDA's guidelines for the acceptance and approval of Iomab-B BLA; (2) the additional analyses, including long-term follow-ups that purportedly demonstrated a trend towards improved Overall Survival that the Company provided to the FDA in an attempt to mitigate Sierra's poor OS data were unlikely to satisfy the FDA's guidelines for the acceptance and approval of Iomab-B BLA; (3) as a result, the FDA would likely refuse to review the Iomab-B BLA or, if it did consider that BLA, that the application in its current form was unlikely to be approved; and (4), as a result, positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

If you currently own ATNM and purchased prior to October 31, 2022 please contact Justin Kuehn, Esq. here, by email at justin@kuehn.law or call (833) 672-0814.  Kuehn Law pays all case costs and does not charge its investor clients. Shareholders should contact the firm immediately as there may be limited time to enforce your rights. 

Why Your Participation Matters:

As a shareholder your voice matters, and by getting involved, you contribute to the integrity and fairness of the financial markets. Your investment. Your voice. Your future.™ 

For additional information, please visit Shareholder Derivative Litigation - Kuehn Law.

Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts:
Kuehn Law, PLLC
Justin Kuehn, Esq.
53 Hill Street, Suite 605
Southampton, NY 11968
justin@kuehn.law
(833) 672-0814

View original content to download multimedia:https://www.prnewswire.com/news-releases/kuehn-law-encourages-investors-of-actinium-pharmaceuticals-inc-to-contact-law-firm-302429675.html

SOURCE Kuehn Law, PLLC